Last reviewed · How we verify
AltSonflex1-2-3 — Competitive Intelligence Brief
phase 2
Sonic hedgehog pathway inhibitor
Sonic hedgehog receptor
Oncology
Biologic
Live · refreshed every 30 min
Target snapshot
AltSonflex1-2-3 (AltSonflex1-2-3) — GlaxoSmithKline. AltSonflex1-2-3 is a small molecule that modulates the sonic hedgehog signaling pathway.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| AltSonflex1-2-3 TARGET | AltSonflex1-2-3 | GlaxoSmithKline | phase 2 | Sonic hedgehog pathway inhibitor | Sonic hedgehog receptor |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Sonic hedgehog pathway inhibitor class)
- GlaxoSmithKline · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- AltSonflex1-2-3 CI watch — RSS
- AltSonflex1-2-3 CI watch — Atom
- AltSonflex1-2-3 CI watch — JSON
- AltSonflex1-2-3 alone — RSS
- Whole Sonic hedgehog pathway inhibitor class — RSS
Cite this brief
Drug Landscape (2026). AltSonflex1-2-3 — Competitive Intelligence Brief. https://druglandscape.com/ci/altsonflex1-2-3. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing